Resources about Shield™ and Guardant Health

Shield Brand Video Transcript

Colorectal cancer—or CRC— is the second-leading cause of cancer-related deaths. However, we can dramatically improve survival outcomes when it’s found early. For example, the 5-year survival rate for Stage 1 & 2 colorectal cancer is 90%.

Screening is the single-best way to detect colorectal cancer. More than 75% of people who died from colorectal cancer were not up to date on screening. Early detection in some cases, can prevent the development of cancer. The current screening modalities, whether stool-based tests or colonoscopy, can deter patients. As Physicians, our goal is to improve early detection and prevent colorectal cancer, so how is the landscape changing to support this important objective? With the innovation of technology and blood-based screening as an option, we can help patients who remain unscreened to get screened.

To help remove CRC barriers and increase compliance results, Guardant Health developed Shield, a highly sensitive blood test that detects early signs of colorectal cancer in average-risk adults. With early detection you are giving patients more time to spend with family.

The goal of screening is to prevent or accurately detect the presence of cancer at its early stages. Therefore, it’s important for a colon cancer screening test to have high sensitivity to find signals of colorectal cancer.

Shield demonstrates high sensitivity by leveraging our advanced multi-modal approach to detect abnormal signals in the bloodstream associated with colorectal cancer. With a simple blood draw, Shield can help break through barriers to help increase compliance rates in average risk adults.

Since our founding over a decade ago, Guardant Health has pioneered a transformation in how we fight cancer by developing blood tests to detect and manage cancer across all stages of the disease. For screening, CRC is our first and lead indication with Shield and soon it will expand into multi-cancer screening, cancers including lung, and others, where we believe cancer screening can save lives.

Help increase screening rates to save lives—with Shield. A simple blood draw. A revolutionary test.

Technology Video Transcript

Colorectal cancer or CRC is the second leading cause of cancer-related deaths. CRC originates as a benign polyp in the colorectal epithelium and may continue to develop into a tumor with no trace of symptoms.

These cancer cells shed circulating tumor DNA or ctDNA into the bloodstream.

Shield is a novel multimodal blood test developed for cancer detection which analyzes ctDNA in the patient’s blood sample.

Shield uses a multimodal approach to detect cancer biomarkers. Genetic mutations associated with cancer are identified using next generation sequencing. Epigenetic modifications affecting which genes are turned on or off are identified by analyzing methylation signals and ctDNA fragmentation patterns that may be associated with cancer.

Shield’s high sensitivity and specificity enable accurate detection of CRC. Becoming a novel solution to help improve screening compliance, thanks to its proprietary multimodal approachand patented digital sequencing platform.

A simple blood draw, a revolutionary test!